An HRE-binding Py-Im polyamide impairs hypoxic signaling in tumors
Abstract
Hypoxic gene expression contributes to the pathogenesis of many diseases, including organ fibrosis, age-related macular degeneration, and cancer. Hypoxia-inducible factor-1 (HIF1), a transcription factor central to the hypoxic gene expression, mediates multiple processes including neovascularization, cancer metastasis, and cell survival. Pyrrole-imidazole polyamide 1 has been shown to inhibit HIF1-mediated gene expression in cell culture but its activity in vivo was unknown. This study reports activity of polyamide 1 in subcutaneous tumors capable of mounting a hypoxic response and showing neovascularization. We show that 1 distributes into subcutaneous tumor xenografts and normal tissues, reduces the expression of proangiogenic and prometastatic factors, inhibits the formation of new tumor blood vessels, and suppresses tumor growth. Tumors treated with 1 show no increase in HIF1α and have reduced ability to adapt to the hypoxic conditions, as evidenced by increased apoptosis in HIF1α-positive regions and the increased proximity of necrotic regions to vasculature. Overall, these results show that a molecule designed to block the transcriptional activity of HIF1 has potent antitumor activity in vivo, consistent with partial inhibition of the tumor hypoxic response.
Additional Information
© 2015 American Association for Cancer Research. Received August 27, 2015. Revision received November 30, 2015. Accepted December 11, 2015. Published Online First December 30, 2015. The authors thank Caltech OLAR for technical assistance with animal experiments and TPCL (UCLA) for assisting with IHC. The authors also thank Drs. Nora Rozengurt and Dinesh Rao (UCLA) for helpful suggestions, discussion and preliminary pathologic evaluation of tumor sections and Drs. Nicholas Nickols and Bogdan Olenyuk for helpful discussions and suggestions. This work was supported by the NIH grant GM-51747. J.O. Szablowski was supported by NIH GM-51747. J.A. Raskatov received postdoctoral support from the Alexander von Humboldt Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Authors' Contributions: Conception and design: J.O. Szablowski, J.A. Raskatov, P.B. Dervan Development of methodology: J.O. Szablowski, J.A. Raskatov Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J.O. Szablowski, J.A. Raskatov Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): J.O. Szablowski, J.A. Raskatov, P.B. Dervan Writing, review, and/or revision of the manuscript: J.O. Szablowski, J.A. Raskatov, P.B. Dervan Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): J.O. Szablowski, J.A. Raskatov Study supervision: P.B. Dervan. No potential conflicts of interest were disclosed.Attached Files
Accepted Version - Mol_Cancer_Ther-2015-Szablowski-1535-7163.MCT-15-0719.pdf
Accepted Version - nihms747346.pdf
Supplemental Material - 154801_1_supp_3204142_nxwkl4.pptx
Supplemental Material - 154801_1_supp_3204143_ny5n25.pptx
Supplemental Material - 154801_1_supp_3204144_ny5l6c.docx
Files
Name | Size | Download all |
---|---|---|
md5:837113713c1ccd696496a89d458e1d42
|
24.9 kB | Download |
md5:2e63e0fac4edd1f5c2f31905903fa286
|
417.0 kB | Download |
md5:c1f21c16c836ba8ef93095f7b0cf5475
|
8.6 MB | Download |
md5:fdbf27a45a5405b00cbfb4891f37599e
|
2.1 MB | Preview Download |
md5:dfa0cbb6646e853d952bfeac1d51e657
|
1.3 MB | Preview Download |
Additional details
- PMCID
- PMC4873353
- Eprint ID
- 63578
- DOI
- 10.1158/1535-7163.MCT-15-0719
- Resolver ID
- CaltechAUTHORS:20160112-091557715
- NIH
- GM-51747
- Alexander von Humboldt Foundation
- Created
-
2016-01-12Created from EPrint's datestamp field
- Updated
-
2022-05-11Created from EPrint's last_modified field